- Previous Close
0.3227 - Open
0.3184 - Bid 0.3155 x 1100
- Ask 0.3151 x 1100
- Day's Range
0.3131 - 0.3240 - 52 Week Range
0.2750 - 0.7500 - Volume
3,154,015 - Avg. Volume
5,061,935 - Market Cap (intraday)
187.27M - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.60
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
www.senseonics.comRecent News: SENS
View MorePerformance Overview: SENS
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SENS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SENS
View MoreValuation Measures
Market Cap
187.27M
Enterprise Value
172.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.77
Price/Book (mrq)
340.53
Enterprise Value/Revenue
7.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.73%
Return on Equity (ttm)
-145.79%
Revenue (ttm)
22.2M
Net Income Avi to Common (ttm)
-80.33M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
74.48M
Total Debt/Equity (mrq)
293.70%
Levered Free Cash Flow (ttm)
-39.06M